The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and systemic toxicities. Antibody–drug conjugates (ADCs) are one of the most rapidly expanding classes of...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Peyton High, Cara Guernsey, Shraddha Subramanian, Joan Jacob, Kendra S. Carmon
Format:	Article
Language:	English
Published:	MDPI AG 2024-07-01
Subjects:	antibody–drug conjugates EGFR HER2 HER3 bispecific antibodies combination therapy
Online Access:	https://www.mdpi.com/1999-4923/16/7/890